Sixteen emerging companies developing innovative mental health solutions will participate in the One Mind Accelerator with intensive mentoring, programming, and critical support to transform the lives of people facing mental illness.

One Mind™, a leading mental health non-profit based in Napa Valley, CA, today announced the 2025 cohort of its flagship One Mind Accelerator program. Thanks to considerable contributions from this year’s supporters, the new cohort will grow from 10 to 16 companies and an official alumni program will offer year-round support for all past and present participants. The 16 early-stage startups spanning Pre-Seed, Seed, and Series A, selected from ~200 applicants, will participate in an intensive 10-week immersion program focused on fundraising, business development, company building, and founder development. By supporting emerging companies through the Accelerator, One Mind seeks to positively impact the lives of people facing mental health challenges by advancing precision psychiatry, and making high quality mental healthcare more accessible, affordable, and equitable.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250224725696/en/

(Graphic: Business Wire)

This is the third cohort for the One Mind Accelerator since the program’s launch in 2023. The sixteen companies selected to participate in the 2025 session are:

  • Ampa Health: Ampa is a health tech startup that is commercializing a scalable brain stimulation technology to treat depression, anxiety, and addiction. Ampa’s groundbreaking One Day treatment delivers a 70% remission rate from depression and anxiety.
  • Attune Neurosciences: Attune Neurosciences has built a non-invasive therapeutic platform to deliver neuromodulation to the deep brain using low-intensity focused ultrasound to address a number of psychiatric, neurological and human performance applications.
  • Cognigenics: Cognigenics is a biotechnology company developing RNA-based long-acting therapeutics for mood disorders, memory loss, and cognitive impairment—offering non-invasive, non-systemic, safe, scalable, and effective solutions that transform lives.
  • Deliberate AI: Deliberate AI advances precision neuroscience and psychiatry by developing multimodal biomarkers and individualized phenotypes. Through Advanced Diagnostics & Monitoring, Precision Therapy Enablement, and Ambient Clinical Intelligence, we enhance both clinical trials and patient care, enabling timely and personalized treatment strategies.
  • Fort Health: Fort Health is a pioneering provider of insurance-based mental health care for children and adolescents, dedicated to improving access and outcomes through collaborative care and evidence-based treatment. By combining innovative technology with expert clinical teams, Fort Health empowers families to navigate mental health challenges with ease and confidence.
  • Freedom Biosciences: Freedom Biosciences is a Yale spin-out and clinical stage biotech company developing next generation depression treatments based on ketamine and 5th-based tryptamines.
  • Humanity Neurotech: Humanity Neurotech is a clinical-stage medical device company developing a new class of transformative technologies for psychiatric and neurological brain disorders by targeting neuroinflammation and mitochondrial dysfunction.
  • Jimini Health: Jimini Health is leveraging AI and deep clinical innovation to develop radically more effective, engaging, and scalable mental health solutions, a critical and necessary innovation when anxiety, depression, and loneliness top the list of unmet medical needs.
  • LunaJoy Health: LunaJoy Health is a behavioral health integration company that works directly with medical doctors and payors to identify unmet service needs for women and deliver, in specialized networks, medication management, therapy and coaching.
  • Metabolic Psychiatry Labs: Metabolic Psychiatry Labs (MPL) treats serious mental illness with metabolic precision remotely through food, real-time data, and expert clinical care. With a Stanford-backed proprietary treatment protocol at its core, MPL provides customized treatments with proven outcomes and supports providers and patients in their treatment with evidence-based nutrition and metabolic therapeutic approaches.
  • Mindstate Design Labs: Mindstate Design Labs is a techbio platform and clinical-stage psychiatric therapeutics company using AI to precision-design psychoactive effects that drive targeted reintegrations of neural connectivity.
  • Neuroblox: is a computational neuroscience platform that simulates patient-specific brain and behavioral responses to clinical interventions and their targets. The platform empowers the development of new drugs and devices, and improves clinical trial success and treatment selection through precision neurotherapeutics.
  • Sanmai Technologies: Sanmai is a neurotechnology company developing non-invasive ultrasound neurotherapeutics for mental health and neurological disorders, combining transcranial ultrasound stimulation with AI-driven software to deliver safe and effective treatments.
  • Slingshot AI: Slingshot AI is an AI research lab building the first foundation model for psychology to make mental healthcare more accessible. The company has built dozens of domain-specific AI models for clinical mental health and tested them in a private beta with 20K+ people.
  • TownHome Health: TownHome Health is a non-traumatic alternative to hospitalization for urgent mental health crises; after staying at calm "Crisis Respite" homes for two weeks, guests reduce their future hospitalizations by 75% with the 24/7 support of our tech-enabled peer clinicians.
  • Xylo Bio: Xylo is pioneering neuroplastogens - next generation therapeutics designed to rewire neural circuits and restore brain function. Combining advanced neuroscience with computational drug discovery, Xylo is developing optimized treatments to revolutionize care for neurological and psychiatric conditions.

“We are honored to welcome these 16 groundbreaking early-stage startups to the 2025 One Mind Accelerator,” said Kathleen M. Pike, PHD, CEO of One Mind. “Advances in mental health understanding, groundbreaking brain research, and rapid developments in AI and computing technology are converging to revolutionize the way we protect mental health and treat mental illness. This One Mind Accelerator cohort is leading the charge, combining scientific, technological, and business model innovation to enhance health and improve quality of life for everyone affected by mental health conditions—which in one way or another includes us all.”

This year’s session commences today with an in-person open week of programming from February 24-28 in Menlo Park, CA, followed by eight weeks of virtual programming, and a final capstone week also to be held in-person in Menlo Park from April 28-30. The One Mind Accelerator leverages One Mind’s extensive network of scientists, investors, entrepreneurs, operators, policymakers, payers, providers, mental health advocates, and more, to serve as mentors and subject matter experts to the selected companies.

"A high level of programmatic customization to each company’s needs and roadmap is a key cornerstone of the program," said Carmine Di Maro, Executive Director of the One Mind Accelerator. "This year, we've built a robust infrastructure of payer, provider, biopharma and medtech, and lived experience advisory councils to deliver unparalleled access and expertise to the cohort. Combined with the support of our world-class network of philanthropic supporters and partners, we're seeking to maximally accelerate innovation in the mental health ecosystem through these companies.”

Key highlights of the 2025 opening week programming include a keynote by Vijay Pande, PHD, Founder and Managing Partner, a16z BioHealth; an Investor Panel with representatives from Khosla Ventures, Satori Neuro, and GreyMatter Capital; a Payer Panel with current and former representatives from Cigna, CVS Health, Headway, and Optum; a Provider Panel with leadership from Massachusetts General Hospital, Kaiser Permanente, and Intermountain Health; and a BioPharma & MedTech Industry roundtable with current and former representatives from Alto Neuroscience, Bristol Myers Squibb, Boehringer Ingelheim, COMPASS Pathways, Johnson & Johnson, Medtronic, Otsuka, amongst others.

As a 501(c)3 nonprofit, One Mind is grateful to receive generous philanthropic support from private donors, foundations, and corporate sponsors who together make the One Mind Accelerator possible. These include Bank of America and the Baszucki Group as lead supporters, as well as support from Alto Neuroscience, Alzheimer’s Foundation of America, Anthony Pritzker Family Foundation, Green Bridge Family Foundation, Indianapolis Colts Kicking The Stigma, Penner Family Foundation, Resonance Philanthropies, TMCity Foundation, Visible Ventures, and Wilson Sonsini Goodrich & Rosati.

For additional information and questions about the One Mind Accelerator, including about the closing week from April 28 to April 30, please contact Carmine Di Maro, Executive Director, One Mind Accelerator: carmine.dimaro@onemind.org

About One Mind™

One Mind is dedicated to advancing research and driving innovation to address today’s mental health crisis. With science as our foundation and people at the heart of our mission, One Mind supports early-career scientists with bold ideas, empowers passionate entrepreneurs developing real-world solutions, and leads a global coalition of business leaders committed to improving mental health in the workplace.

Founded in 1995 by Shari and Garen Staglin following their son Brandon’s diagnosis with schizophrenia, One Mind was created to bridge critical gaps in mental health research funding and patient support. Guided by this enduring purpose, One Mind strives to transform knowledge into actionable solutions that foster mental health and healing for individuals whose lives are impacted by mental illness.

One Mind, pr@onemind.org